General Oncology
About
General Oncology is a clinical-stage drug developer in Newton focused on cancers that resist current treatment. Its drug candidates are designed to overcome tumor drug resistance while minimizing chronic toxicity. The company’s programs target metastatic cancers and other proliferative diseases where current therapies provide limited durable benefit, and it pursues both a clinical-stage cancer program and a preclinical candidate aimed at eye disease.
Its lead program, GO-4, is a multi-modal investigational therapy designed to attack cancer cells through synergistic drug interactions that produce multiple independent mechanisms of action. In the phase 1 SHARON trial of stage IV BRCA-associated pancreatic cancer, 13 patients showed a median overall survival of 37.5 months, two remained disease-free at 54 and 37 months, and no chronic toxicities were observed. Results were presented at the ESMO 2025 Congress.
What to Know
- A second candidate, GO-2301, is in preclinical development for wet age-related macular degeneration and diabetic retinopathy.
- GO-2301 may also have future applications in oncology.
- GO-4 is being developed for metastatic cancers, including pancreatic cancer.
- The company is a member of the Charles River Regional Chamber.
Is this your business?
Claim it to add hours, photos, a description and a spotlight story.